These findings supported the evaluation of potential synergy between CAN-2409 treatment and anti–CTLA-4 antibodies, and it was found that the CAN-2409–dependent changes in the tumor immune compartment support enhanced tumor control with combination therapy. This evidence concerns the gene CTLA4 and neoplasm.